Global Dermatology Otc Drug Market

Dermatology Otc Drug Comprehensive Study by Type (Anti-Fungal Medicines, Anti-Infective Medicines, Anti-Inflammatory, Anti-Pruritic, Anti-Psoriasis Medication, Others), Application (Hospital, Drug Store, Other), Form (Cream, Liquid), Distribution Channels (Online, Supermarket, Hypermarket, Others) Players and Region - Global Market Outlook to 2027

Dermatology Otc Drug Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Dermatology Otc Drug?
Dermatology OTC drugs are also known as nonprescription medicines or OTC medicines. All of these terms refer to medications that can be purchased without a prescription. They are safe and effective when used as directed on the label and by your health care professional. Dermatologists must be familiar with the safety, utility, and tolerability of a wide range of OTC products. The role of the US Food and Drug Administration in regulating the safety of over-the-counter (OTC) products is discussed in this article. Additionally, resources are reviewed to assist clinicians in learning about the pharmacology and tolerability of OTC products. Antineoplastic are drugs used to treat cancerous tumors. ANTIPSORIATICS are medications used to treat psoriasis. BIOLOGIC RESPONSE MODIFIERS These medications exhibit immunoregulatory properties. BRAF inhibitors are antineoplastic drugs that target BRAF gene mutations.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)
Key Companies ProfiledSun Pharmaceutical (India), Mylan (United States), Dr. Reddy`s (India), Lupin Limited (India), Bayer (Germany), Aurobindo Pharma (India), Johnson & Johnson (United States), GSK plc (United Kingdom), Teva Pharmaceuticals (Israel) and Novartis (Switzerland)


The study covers a detailed analysis segmented by key business segments i.e. by type (Anti-Fungal Medicines, Anti-Infective Medicines, Anti-Inflammatory, Anti-Pruritic, Anti-Psoriasis Medication and Others) , by application (Hospital, Drug Store and Other) and major geographies. Research Analyst at AMA predicts that India Players will contribute to the maximum growth of Global Dermatology Otc Drug market throughout the predicted period.

The competition is expected to become even more intense in the years to come due to the entry of several new players in the market. To help clients improve their revenue shares in the market, this research study provides an in-depth analysis of the market’s competitive landscape and offers information on the products offered by various leading companies. Additionally, this Dermatology Otc Drug market report suggests strategies that Players can follow and highlights key areas they should focus on, in order to take maximum benefits of growth opportunities.

The report offers several leading Players, some of them are Sun Pharmaceutical (India), Mylan (United States), Dr. Reddy`s (India), Lupin Limited (India), Bayer (Germany), Aurobindo Pharma (India), Johnson & Johnson (United States), GSK plc (United Kingdom), Teva Pharmaceuticals (Israel) and Novartis (Switzerland).

Market Overview:
On 27th May 2022, Sun Pharmaceutical Industries announced that its Romanian subsidiary, S.C. Terapia SA, had purchased the Uractiv portfolio from Fiterman Pharma in Romania for an undisclosed sum.
OTC medicines for allergies, fever, vomiting, muscle pain, inflammatory conditions, antacids, external skin preparations, and hormonal contraceptives were considered for inclusion in the list. The subcommittee investigated the situation and prepared a report, which was sent to the DCC for review. The report addressed various aspects of OTC drugs, including their definition, basic characteristics, classification, list of OTC drugs, and regulation of the prescription drug to OTC drug switch process; regulation of new OTC drug approval and manufacturing; labeling, distribution, sale; advertisement; and pricing of OTC drugs.
The competitive landscape of the global dermatology OTC drugs market provides information on a competitor. The following information is included: company overview, financials, revenue generated, market potential, R&D investment, new market initiatives, international reach, industrial plants and facilities, production capacities, company assets, and weaknesses, product launch, item width and breadth, and application dominance. The data points presented above are solely related to the company’s focus on the global dermatology OTC drug market.

Influencing Trend:
Introduction of Home Sleep Test Kits and Wearable Monitors, High Demand for Quick Diagnosis and Rising Expenditure on Personal Care

Market Growth Drivers:
Increasing Incidence of Dermatology Otc Drug and Rising Geriatric Population and Associated Sleep Otc Drug

Challenges:
Side Effect Related to Dermatology Otc Drugs and Companies Have To Comply With FDA Regulation

Restraints:
Strict Government Regulations and High Cost of Drug Development

Opportunities:
Development of Innovative Products, Growing New Technology of Manufacturers Otc Drugs and Increasing Government Initiative of Supporting Drugs

Key highlights of the Global Dermatology Otc Drug market Study:
• CAGR of the market during the forecast period 2021-2027
• In-depth information on growth factors that will accelerate the Dermatology Otc Drug market in next few years.
• Detailed Insights on futuristic trends and changing consumer behavior
• Forecast of the Global Dermatology Otc Drug market size and its contribution to the parent market by type, application and by country.
• A broad view of customer demand
• Uncover market’s competitive landscape and in-depth information on various Players
• Comprehensive information about factors that will challenge the growth of Dermatology Otc Drug Players

Transformation and Important Triggers:
Business transformation has taken hold across the broad corporate landscape due to the confluence of several important triggers, including:
• A tipping point in globalization
• A major slowdown in Western economies
• Significant shifts in technology and cost structure
• The challenges of regulatory compliance
• New forms of competition developing

Research Methodology:

The top-down and bottom-up approaches are used to estimate and validate the size of the Global Dermatology Otc Drug market.
In order to reach an exhaustive list of functional and relevant players, various industry classification standards are closely followed such as NAICS, ICB, and SIC to penetrate deep into important geographies by players, and a thorough validation test is conducted to reach the most relevant players for survey in Dermatology Otc Drug market.
In order to make a priority list sorting is done based on revenue generated based on the latest reporting, using paid databases such as Factiva, Bloomberg, etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment> by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Dermatology Otc Drug Manufacturers, Wholesalers, Distributors and Dermatology Otc Drug, Government Bodies, End-Users and Others.
This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth, etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that include Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases, etc.

Report Objectives / Segmentation Covered

By Type
  • Anti-Fungal Medicines
  • Anti-Infective Medicines
  • Anti-Inflammatory
  • Anti-Pruritic
  • Anti-Psoriasis Medication
  • Others
By Application
  • Hospital
  • Drug Store
  • Other
By Form
  • Cream
  • Liquid

By Distribution Channels
  • Online
  • Supermarket
  • Hypermarket
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Incidence of Dermatology Otc Drug
      • 3.2.2. Rising Geriatric Population and Associated Sleep Otc Drug
    • 3.3. Market Challenges
      • 3.3.1. Side Effect Related to Dermatology Otc Drugs
      • 3.3.2. Companies Have To Comply With FDA Regulation
    • 3.4. Market Trends
      • 3.4.1. Introduction of Home Sleep Test Kits and Wearable Monitors
      • 3.4.2. High Demand for Quick Diagnosis
      • 3.4.3. Rising Expenditure on Personal Care
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Dermatology Otc Drug, by Type, Application, Form, Distribution Channels and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Dermatology Otc Drug (Value)
      • 5.2.1. Global Dermatology Otc Drug by: Type (Value)
        • 5.2.1.1. Anti-Fungal Medicines
        • 5.2.1.2. Anti-Infective Medicines
        • 5.2.1.3. Anti-Inflammatory
        • 5.2.1.4. Anti-Pruritic
        • 5.2.1.5. Anti-Psoriasis Medication
        • 5.2.1.6. Others
      • 5.2.2. Global Dermatology Otc Drug by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Drug Store
        • 5.2.2.3. Other
      • 5.2.3. Global Dermatology Otc Drug by: Form (Value)
        • 5.2.3.1. Cream
        • 5.2.3.2. Liquid
      • 5.2.4. Global Dermatology Otc Drug by: Distribution Channels (Value)
        • 5.2.4.1. Online
        • 5.2.4.2. Supermarket
        • 5.2.4.3. Hypermarket
        • 5.2.4.4. Others
      • 5.2.5. Global Dermatology Otc Drug Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Australia
          • 5.2.5.2.6. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Dermatology Otc Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Sun Pharmaceutical (India)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Mylan (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Dr. Reddy`s (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Lupin Limited (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bayer (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Aurobindo Pharma (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Johnson & Johnson (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. GSK plc (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Teva Pharmaceuticals (Israel)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Novartis (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Dermatology Otc Drug Sale, by Type, Application, Form, Distribution Channels and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Dermatology Otc Drug (Value)
      • 7.2.1. Global Dermatology Otc Drug by: Type (Value)
        • 7.2.1.1. Anti-Fungal Medicines
        • 7.2.1.2. Anti-Infective Medicines
        • 7.2.1.3. Anti-Inflammatory
        • 7.2.1.4. Anti-Pruritic
        • 7.2.1.5. Anti-Psoriasis Medication
        • 7.2.1.6. Others
      • 7.2.2. Global Dermatology Otc Drug by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Drug Store
        • 7.2.2.3. Other
      • 7.2.3. Global Dermatology Otc Drug by: Form (Value)
        • 7.2.3.1. Cream
        • 7.2.3.2. Liquid
      • 7.2.4. Global Dermatology Otc Drug by: Distribution Channels (Value)
        • 7.2.4.1. Online
        • 7.2.4.2. Supermarket
        • 7.2.4.3. Hypermarket
        • 7.2.4.4. Others
      • 7.2.5. Global Dermatology Otc Drug Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Australia
          • 7.2.5.2.6. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Dermatology Otc Drug: by Type(USD Million)
  • Table 2. Dermatology Otc Drug Anti-Fungal Medicines , by Region USD Million (2016-2021)
  • Table 3. Dermatology Otc Drug Anti-Infective Medicines , by Region USD Million (2016-2021)
  • Table 4. Dermatology Otc Drug Anti-Inflammatory , by Region USD Million (2016-2021)
  • Table 5. Dermatology Otc Drug Anti-Pruritic , by Region USD Million (2016-2021)
  • Table 6. Dermatology Otc Drug Anti-Psoriasis Medication , by Region USD Million (2016-2021)
  • Table 7. Dermatology Otc Drug Others , by Region USD Million (2016-2021)
  • Table 8. Dermatology Otc Drug: by Application(USD Million)
  • Table 9. Dermatology Otc Drug Hospital , by Region USD Million (2016-2021)
  • Table 10. Dermatology Otc Drug Drug Store , by Region USD Million (2016-2021)
  • Table 11. Dermatology Otc Drug Other , by Region USD Million (2016-2021)
  • Table 12. Dermatology Otc Drug: by Form(USD Million)
  • Table 13. Dermatology Otc Drug Cream , by Region USD Million (2016-2021)
  • Table 14. Dermatology Otc Drug Liquid , by Region USD Million (2016-2021)
  • Table 15. Dermatology Otc Drug: by Distribution Channels(USD Million)
  • Table 16. Dermatology Otc Drug Online , by Region USD Million (2016-2021)
  • Table 17. Dermatology Otc Drug Supermarket , by Region USD Million (2016-2021)
  • Table 18. Dermatology Otc Drug Hypermarket , by Region USD Million (2016-2021)
  • Table 19. Dermatology Otc Drug Others , by Region USD Million (2016-2021)
  • Table 20. South America Dermatology Otc Drug, by Country USD Million (2016-2021)
  • Table 21. South America Dermatology Otc Drug, by Type USD Million (2016-2021)
  • Table 22. South America Dermatology Otc Drug, by Application USD Million (2016-2021)
  • Table 23. South America Dermatology Otc Drug, by Form USD Million (2016-2021)
  • Table 24. South America Dermatology Otc Drug, by Distribution Channels USD Million (2016-2021)
  • Table 25. Brazil Dermatology Otc Drug, by Type USD Million (2016-2021)
  • Table 26. Brazil Dermatology Otc Drug, by Application USD Million (2016-2021)
  • Table 27. Brazil Dermatology Otc Drug, by Form USD Million (2016-2021)
  • Table 28. Brazil Dermatology Otc Drug, by Distribution Channels USD Million (2016-2021)
  • Table 29. Argentina Dermatology Otc Drug, by Type USD Million (2016-2021)
  • Table 30. Argentina Dermatology Otc Drug, by Application USD Million (2016-2021)
  • Table 31. Argentina Dermatology Otc Drug, by Form USD Million (2016-2021)
  • Table 32. Argentina Dermatology Otc Drug, by Distribution Channels USD Million (2016-2021)
  • Table 33. Rest of South America Dermatology Otc Drug, by Type USD Million (2016-2021)
  • Table 34. Rest of South America Dermatology Otc Drug, by Application USD Million (2016-2021)
  • Table 35. Rest of South America Dermatology Otc Drug, by Form USD Million (2016-2021)
  • Table 36. Rest of South America Dermatology Otc Drug, by Distribution Channels USD Million (2016-2021)
  • Table 37. Asia Pacific Dermatology Otc Drug, by Country USD Million (2016-2021)
  • Table 38. Asia Pacific Dermatology Otc Drug, by Type USD Million (2016-2021)
  • Table 39. Asia Pacific Dermatology Otc Drug, by Application USD Million (2016-2021)
  • Table 40. Asia Pacific Dermatology Otc Drug, by Form USD Million (2016-2021)
  • Table 41. Asia Pacific Dermatology Otc Drug, by Distribution Channels USD Million (2016-2021)
  • Table 42. China Dermatology Otc Drug, by Type USD Million (2016-2021)
  • Table 43. China Dermatology Otc Drug, by Application USD Million (2016-2021)
  • Table 44. China Dermatology Otc Drug, by Form USD Million (2016-2021)
  • Table 45. China Dermatology Otc Drug, by Distribution Channels USD Million (2016-2021)
  • Table 46. Japan Dermatology Otc Drug, by Type USD Million (2016-2021)
  • Table 47. Japan Dermatology Otc Drug, by Application USD Million (2016-2021)
  • Table 48. Japan Dermatology Otc Drug, by Form USD Million (2016-2021)
  • Table 49. Japan Dermatology Otc Drug, by Distribution Channels USD Million (2016-2021)
  • Table 50. India Dermatology Otc Drug, by Type USD Million (2016-2021)
  • Table 51. India Dermatology Otc Drug, by Application USD Million (2016-2021)
  • Table 52. India Dermatology Otc Drug, by Form USD Million (2016-2021)
  • Table 53. India Dermatology Otc Drug, by Distribution Channels USD Million (2016-2021)
  • Table 54. South Korea Dermatology Otc Drug, by Type USD Million (2016-2021)
  • Table 55. South Korea Dermatology Otc Drug, by Application USD Million (2016-2021)
  • Table 56. South Korea Dermatology Otc Drug, by Form USD Million (2016-2021)
  • Table 57. South Korea Dermatology Otc Drug, by Distribution Channels USD Million (2016-2021)
  • Table 58. Australia Dermatology Otc Drug, by Type USD Million (2016-2021)
  • Table 59. Australia Dermatology Otc Drug, by Application USD Million (2016-2021)
  • Table 60. Australia Dermatology Otc Drug, by Form USD Million (2016-2021)
  • Table 61. Australia Dermatology Otc Drug, by Distribution Channels USD Million (2016-2021)
  • Table 62. Rest of Asia-Pacific Dermatology Otc Drug, by Type USD Million (2016-2021)
  • Table 63. Rest of Asia-Pacific Dermatology Otc Drug, by Application USD Million (2016-2021)
  • Table 64. Rest of Asia-Pacific Dermatology Otc Drug, by Form USD Million (2016-2021)
  • Table 65. Rest of Asia-Pacific Dermatology Otc Drug, by Distribution Channels USD Million (2016-2021)
  • Table 66. Europe Dermatology Otc Drug, by Country USD Million (2016-2021)
  • Table 67. Europe Dermatology Otc Drug, by Type USD Million (2016-2021)
  • Table 68. Europe Dermatology Otc Drug, by Application USD Million (2016-2021)
  • Table 69. Europe Dermatology Otc Drug, by Form USD Million (2016-2021)
  • Table 70. Europe Dermatology Otc Drug, by Distribution Channels USD Million (2016-2021)
  • Table 71. Germany Dermatology Otc Drug, by Type USD Million (2016-2021)
  • Table 72. Germany Dermatology Otc Drug, by Application USD Million (2016-2021)
  • Table 73. Germany Dermatology Otc Drug, by Form USD Million (2016-2021)
  • Table 74. Germany Dermatology Otc Drug, by Distribution Channels USD Million (2016-2021)
  • Table 75. France Dermatology Otc Drug, by Type USD Million (2016-2021)
  • Table 76. France Dermatology Otc Drug, by Application USD Million (2016-2021)
  • Table 77. France Dermatology Otc Drug, by Form USD Million (2016-2021)
  • Table 78. France Dermatology Otc Drug, by Distribution Channels USD Million (2016-2021)
  • Table 79. Italy Dermatology Otc Drug, by Type USD Million (2016-2021)
  • Table 80. Italy Dermatology Otc Drug, by Application USD Million (2016-2021)
  • Table 81. Italy Dermatology Otc Drug, by Form USD Million (2016-2021)
  • Table 82. Italy Dermatology Otc Drug, by Distribution Channels USD Million (2016-2021)
  • Table 83. United Kingdom Dermatology Otc Drug, by Type USD Million (2016-2021)
  • Table 84. United Kingdom Dermatology Otc Drug, by Application USD Million (2016-2021)
  • Table 85. United Kingdom Dermatology Otc Drug, by Form USD Million (2016-2021)
  • Table 86. United Kingdom Dermatology Otc Drug, by Distribution Channels USD Million (2016-2021)
  • Table 87. Netherlands Dermatology Otc Drug, by Type USD Million (2016-2021)
  • Table 88. Netherlands Dermatology Otc Drug, by Application USD Million (2016-2021)
  • Table 89. Netherlands Dermatology Otc Drug, by Form USD Million (2016-2021)
  • Table 90. Netherlands Dermatology Otc Drug, by Distribution Channels USD Million (2016-2021)
  • Table 91. Rest of Europe Dermatology Otc Drug, by Type USD Million (2016-2021)
  • Table 92. Rest of Europe Dermatology Otc Drug, by Application USD Million (2016-2021)
  • Table 93. Rest of Europe Dermatology Otc Drug, by Form USD Million (2016-2021)
  • Table 94. Rest of Europe Dermatology Otc Drug, by Distribution Channels USD Million (2016-2021)
  • Table 95. MEA Dermatology Otc Drug, by Country USD Million (2016-2021)
  • Table 96. MEA Dermatology Otc Drug, by Type USD Million (2016-2021)
  • Table 97. MEA Dermatology Otc Drug, by Application USD Million (2016-2021)
  • Table 98. MEA Dermatology Otc Drug, by Form USD Million (2016-2021)
  • Table 99. MEA Dermatology Otc Drug, by Distribution Channels USD Million (2016-2021)
  • Table 100. Middle East Dermatology Otc Drug, by Type USD Million (2016-2021)
  • Table 101. Middle East Dermatology Otc Drug, by Application USD Million (2016-2021)
  • Table 102. Middle East Dermatology Otc Drug, by Form USD Million (2016-2021)
  • Table 103. Middle East Dermatology Otc Drug, by Distribution Channels USD Million (2016-2021)
  • Table 104. Africa Dermatology Otc Drug, by Type USD Million (2016-2021)
  • Table 105. Africa Dermatology Otc Drug, by Application USD Million (2016-2021)
  • Table 106. Africa Dermatology Otc Drug, by Form USD Million (2016-2021)
  • Table 107. Africa Dermatology Otc Drug, by Distribution Channels USD Million (2016-2021)
  • Table 108. North America Dermatology Otc Drug, by Country USD Million (2016-2021)
  • Table 109. North America Dermatology Otc Drug, by Type USD Million (2016-2021)
  • Table 110. North America Dermatology Otc Drug, by Application USD Million (2016-2021)
  • Table 111. North America Dermatology Otc Drug, by Form USD Million (2016-2021)
  • Table 112. North America Dermatology Otc Drug, by Distribution Channels USD Million (2016-2021)
  • Table 113. United States Dermatology Otc Drug, by Type USD Million (2016-2021)
  • Table 114. United States Dermatology Otc Drug, by Application USD Million (2016-2021)
  • Table 115. United States Dermatology Otc Drug, by Form USD Million (2016-2021)
  • Table 116. United States Dermatology Otc Drug, by Distribution Channels USD Million (2016-2021)
  • Table 117. Canada Dermatology Otc Drug, by Type USD Million (2016-2021)
  • Table 118. Canada Dermatology Otc Drug, by Application USD Million (2016-2021)
  • Table 119. Canada Dermatology Otc Drug, by Form USD Million (2016-2021)
  • Table 120. Canada Dermatology Otc Drug, by Distribution Channels USD Million (2016-2021)
  • Table 121. Mexico Dermatology Otc Drug, by Type USD Million (2016-2021)
  • Table 122. Mexico Dermatology Otc Drug, by Application USD Million (2016-2021)
  • Table 123. Mexico Dermatology Otc Drug, by Form USD Million (2016-2021)
  • Table 124. Mexico Dermatology Otc Drug, by Distribution Channels USD Million (2016-2021)
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Dermatology Otc Drug: by Type(USD Million)
  • Table 136. Dermatology Otc Drug Anti-Fungal Medicines , by Region USD Million (2022-2027)
  • Table 137. Dermatology Otc Drug Anti-Infective Medicines , by Region USD Million (2022-2027)
  • Table 138. Dermatology Otc Drug Anti-Inflammatory , by Region USD Million (2022-2027)
  • Table 139. Dermatology Otc Drug Anti-Pruritic , by Region USD Million (2022-2027)
  • Table 140. Dermatology Otc Drug Anti-Psoriasis Medication , by Region USD Million (2022-2027)
  • Table 141. Dermatology Otc Drug Others , by Region USD Million (2022-2027)
  • Table 142. Dermatology Otc Drug: by Application(USD Million)
  • Table 143. Dermatology Otc Drug Hospital , by Region USD Million (2022-2027)
  • Table 144. Dermatology Otc Drug Drug Store , by Region USD Million (2022-2027)
  • Table 145. Dermatology Otc Drug Other , by Region USD Million (2022-2027)
  • Table 146. Dermatology Otc Drug: by Form(USD Million)
  • Table 147. Dermatology Otc Drug Cream , by Region USD Million (2022-2027)
  • Table 148. Dermatology Otc Drug Liquid , by Region USD Million (2022-2027)
  • Table 149. Dermatology Otc Drug: by Distribution Channels(USD Million)
  • Table 150. Dermatology Otc Drug Online , by Region USD Million (2022-2027)
  • Table 151. Dermatology Otc Drug Supermarket , by Region USD Million (2022-2027)
  • Table 152. Dermatology Otc Drug Hypermarket , by Region USD Million (2022-2027)
  • Table 153. Dermatology Otc Drug Others , by Region USD Million (2022-2027)
  • Table 154. South America Dermatology Otc Drug, by Country USD Million (2022-2027)
  • Table 155. South America Dermatology Otc Drug, by Type USD Million (2022-2027)
  • Table 156. South America Dermatology Otc Drug, by Application USD Million (2022-2027)
  • Table 157. South America Dermatology Otc Drug, by Form USD Million (2022-2027)
  • Table 158. South America Dermatology Otc Drug, by Distribution Channels USD Million (2022-2027)
  • Table 159. Brazil Dermatology Otc Drug, by Type USD Million (2022-2027)
  • Table 160. Brazil Dermatology Otc Drug, by Application USD Million (2022-2027)
  • Table 161. Brazil Dermatology Otc Drug, by Form USD Million (2022-2027)
  • Table 162. Brazil Dermatology Otc Drug, by Distribution Channels USD Million (2022-2027)
  • Table 163. Argentina Dermatology Otc Drug, by Type USD Million (2022-2027)
  • Table 164. Argentina Dermatology Otc Drug, by Application USD Million (2022-2027)
  • Table 165. Argentina Dermatology Otc Drug, by Form USD Million (2022-2027)
  • Table 166. Argentina Dermatology Otc Drug, by Distribution Channels USD Million (2022-2027)
  • Table 167. Rest of South America Dermatology Otc Drug, by Type USD Million (2022-2027)
  • Table 168. Rest of South America Dermatology Otc Drug, by Application USD Million (2022-2027)
  • Table 169. Rest of South America Dermatology Otc Drug, by Form USD Million (2022-2027)
  • Table 170. Rest of South America Dermatology Otc Drug, by Distribution Channels USD Million (2022-2027)
  • Table 171. Asia Pacific Dermatology Otc Drug, by Country USD Million (2022-2027)
  • Table 172. Asia Pacific Dermatology Otc Drug, by Type USD Million (2022-2027)
  • Table 173. Asia Pacific Dermatology Otc Drug, by Application USD Million (2022-2027)
  • Table 174. Asia Pacific Dermatology Otc Drug, by Form USD Million (2022-2027)
  • Table 175. Asia Pacific Dermatology Otc Drug, by Distribution Channels USD Million (2022-2027)
  • Table 176. China Dermatology Otc Drug, by Type USD Million (2022-2027)
  • Table 177. China Dermatology Otc Drug, by Application USD Million (2022-2027)
  • Table 178. China Dermatology Otc Drug, by Form USD Million (2022-2027)
  • Table 179. China Dermatology Otc Drug, by Distribution Channels USD Million (2022-2027)
  • Table 180. Japan Dermatology Otc Drug, by Type USD Million (2022-2027)
  • Table 181. Japan Dermatology Otc Drug, by Application USD Million (2022-2027)
  • Table 182. Japan Dermatology Otc Drug, by Form USD Million (2022-2027)
  • Table 183. Japan Dermatology Otc Drug, by Distribution Channels USD Million (2022-2027)
  • Table 184. India Dermatology Otc Drug, by Type USD Million (2022-2027)
  • Table 185. India Dermatology Otc Drug, by Application USD Million (2022-2027)
  • Table 186. India Dermatology Otc Drug, by Form USD Million (2022-2027)
  • Table 187. India Dermatology Otc Drug, by Distribution Channels USD Million (2022-2027)
  • Table 188. South Korea Dermatology Otc Drug, by Type USD Million (2022-2027)
  • Table 189. South Korea Dermatology Otc Drug, by Application USD Million (2022-2027)
  • Table 190. South Korea Dermatology Otc Drug, by Form USD Million (2022-2027)
  • Table 191. South Korea Dermatology Otc Drug, by Distribution Channels USD Million (2022-2027)
  • Table 192. Australia Dermatology Otc Drug, by Type USD Million (2022-2027)
  • Table 193. Australia Dermatology Otc Drug, by Application USD Million (2022-2027)
  • Table 194. Australia Dermatology Otc Drug, by Form USD Million (2022-2027)
  • Table 195. Australia Dermatology Otc Drug, by Distribution Channels USD Million (2022-2027)
  • Table 196. Rest of Asia-Pacific Dermatology Otc Drug, by Type USD Million (2022-2027)
  • Table 197. Rest of Asia-Pacific Dermatology Otc Drug, by Application USD Million (2022-2027)
  • Table 198. Rest of Asia-Pacific Dermatology Otc Drug, by Form USD Million (2022-2027)
  • Table 199. Rest of Asia-Pacific Dermatology Otc Drug, by Distribution Channels USD Million (2022-2027)
  • Table 200. Europe Dermatology Otc Drug, by Country USD Million (2022-2027)
  • Table 201. Europe Dermatology Otc Drug, by Type USD Million (2022-2027)
  • Table 202. Europe Dermatology Otc Drug, by Application USD Million (2022-2027)
  • Table 203. Europe Dermatology Otc Drug, by Form USD Million (2022-2027)
  • Table 204. Europe Dermatology Otc Drug, by Distribution Channels USD Million (2022-2027)
  • Table 205. Germany Dermatology Otc Drug, by Type USD Million (2022-2027)
  • Table 206. Germany Dermatology Otc Drug, by Application USD Million (2022-2027)
  • Table 207. Germany Dermatology Otc Drug, by Form USD Million (2022-2027)
  • Table 208. Germany Dermatology Otc Drug, by Distribution Channels USD Million (2022-2027)
  • Table 209. France Dermatology Otc Drug, by Type USD Million (2022-2027)
  • Table 210. France Dermatology Otc Drug, by Application USD Million (2022-2027)
  • Table 211. France Dermatology Otc Drug, by Form USD Million (2022-2027)
  • Table 212. France Dermatology Otc Drug, by Distribution Channels USD Million (2022-2027)
  • Table 213. Italy Dermatology Otc Drug, by Type USD Million (2022-2027)
  • Table 214. Italy Dermatology Otc Drug, by Application USD Million (2022-2027)
  • Table 215. Italy Dermatology Otc Drug, by Form USD Million (2022-2027)
  • Table 216. Italy Dermatology Otc Drug, by Distribution Channels USD Million (2022-2027)
  • Table 217. United Kingdom Dermatology Otc Drug, by Type USD Million (2022-2027)
  • Table 218. United Kingdom Dermatology Otc Drug, by Application USD Million (2022-2027)
  • Table 219. United Kingdom Dermatology Otc Drug, by Form USD Million (2022-2027)
  • Table 220. United Kingdom Dermatology Otc Drug, by Distribution Channels USD Million (2022-2027)
  • Table 221. Netherlands Dermatology Otc Drug, by Type USD Million (2022-2027)
  • Table 222. Netherlands Dermatology Otc Drug, by Application USD Million (2022-2027)
  • Table 223. Netherlands Dermatology Otc Drug, by Form USD Million (2022-2027)
  • Table 224. Netherlands Dermatology Otc Drug, by Distribution Channels USD Million (2022-2027)
  • Table 225. Rest of Europe Dermatology Otc Drug, by Type USD Million (2022-2027)
  • Table 226. Rest of Europe Dermatology Otc Drug, by Application USD Million (2022-2027)
  • Table 227. Rest of Europe Dermatology Otc Drug, by Form USD Million (2022-2027)
  • Table 228. Rest of Europe Dermatology Otc Drug, by Distribution Channels USD Million (2022-2027)
  • Table 229. MEA Dermatology Otc Drug, by Country USD Million (2022-2027)
  • Table 230. MEA Dermatology Otc Drug, by Type USD Million (2022-2027)
  • Table 231. MEA Dermatology Otc Drug, by Application USD Million (2022-2027)
  • Table 232. MEA Dermatology Otc Drug, by Form USD Million (2022-2027)
  • Table 233. MEA Dermatology Otc Drug, by Distribution Channels USD Million (2022-2027)
  • Table 234. Middle East Dermatology Otc Drug, by Type USD Million (2022-2027)
  • Table 235. Middle East Dermatology Otc Drug, by Application USD Million (2022-2027)
  • Table 236. Middle East Dermatology Otc Drug, by Form USD Million (2022-2027)
  • Table 237. Middle East Dermatology Otc Drug, by Distribution Channels USD Million (2022-2027)
  • Table 238. Africa Dermatology Otc Drug, by Type USD Million (2022-2027)
  • Table 239. Africa Dermatology Otc Drug, by Application USD Million (2022-2027)
  • Table 240. Africa Dermatology Otc Drug, by Form USD Million (2022-2027)
  • Table 241. Africa Dermatology Otc Drug, by Distribution Channels USD Million (2022-2027)
  • Table 242. North America Dermatology Otc Drug, by Country USD Million (2022-2027)
  • Table 243. North America Dermatology Otc Drug, by Type USD Million (2022-2027)
  • Table 244. North America Dermatology Otc Drug, by Application USD Million (2022-2027)
  • Table 245. North America Dermatology Otc Drug, by Form USD Million (2022-2027)
  • Table 246. North America Dermatology Otc Drug, by Distribution Channels USD Million (2022-2027)
  • Table 247. United States Dermatology Otc Drug, by Type USD Million (2022-2027)
  • Table 248. United States Dermatology Otc Drug, by Application USD Million (2022-2027)
  • Table 249. United States Dermatology Otc Drug, by Form USD Million (2022-2027)
  • Table 250. United States Dermatology Otc Drug, by Distribution Channels USD Million (2022-2027)
  • Table 251. Canada Dermatology Otc Drug, by Type USD Million (2022-2027)
  • Table 252. Canada Dermatology Otc Drug, by Application USD Million (2022-2027)
  • Table 253. Canada Dermatology Otc Drug, by Form USD Million (2022-2027)
  • Table 254. Canada Dermatology Otc Drug, by Distribution Channels USD Million (2022-2027)
  • Table 255. Mexico Dermatology Otc Drug, by Type USD Million (2022-2027)
  • Table 256. Mexico Dermatology Otc Drug, by Application USD Million (2022-2027)
  • Table 257. Mexico Dermatology Otc Drug, by Form USD Million (2022-2027)
  • Table 258. Mexico Dermatology Otc Drug, by Distribution Channels USD Million (2022-2027)
  • Table 259. Research Programs/Design for This Report
  • Table 260. Key Data Information from Secondary Sources
  • Table 261. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Dermatology Otc Drug: by Type USD Million (2016-2021)
  • Figure 5. Global Dermatology Otc Drug: by Application USD Million (2016-2021)
  • Figure 6. Global Dermatology Otc Drug: by Form USD Million (2016-2021)
  • Figure 7. Global Dermatology Otc Drug: by Distribution Channels USD Million (2016-2021)
  • Figure 8. South America Dermatology Otc Drug Share (%), by Country
  • Figure 9. Asia Pacific Dermatology Otc Drug Share (%), by Country
  • Figure 10. Europe Dermatology Otc Drug Share (%), by Country
  • Figure 11. MEA Dermatology Otc Drug Share (%), by Country
  • Figure 12. North America Dermatology Otc Drug Share (%), by Country
  • Figure 13. Global Dermatology Otc Drug share by Players 2021 (%)
  • Figure 14. Global Dermatology Otc Drug share by Players (Top 3) 2021(%)
  • Figure 15. Global Dermatology Otc Drug share by Players (Top 5) 2021(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Sun Pharmaceutical (India) Revenue, Net Income and Gross profit
  • Figure 18. Sun Pharmaceutical (India) Revenue: by Geography 2021
  • Figure 19. Mylan (United States) Revenue, Net Income and Gross profit
  • Figure 20. Mylan (United States) Revenue: by Geography 2021
  • Figure 21. Dr. Reddy`s (India) Revenue, Net Income and Gross profit
  • Figure 22. Dr. Reddy`s (India) Revenue: by Geography 2021
  • Figure 23. Lupin Limited (India) Revenue, Net Income and Gross profit
  • Figure 24. Lupin Limited (India) Revenue: by Geography 2021
  • Figure 25. Bayer (Germany) Revenue, Net Income and Gross profit
  • Figure 26. Bayer (Germany) Revenue: by Geography 2021
  • Figure 27. Aurobindo Pharma (India) Revenue, Net Income and Gross profit
  • Figure 28. Aurobindo Pharma (India) Revenue: by Geography 2021
  • Figure 29. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 30. Johnson & Johnson (United States) Revenue: by Geography 2021
  • Figure 31. GSK plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 32. GSK plc (United Kingdom) Revenue: by Geography 2021
  • Figure 33. Teva Pharmaceuticals (Israel) Revenue, Net Income and Gross profit
  • Figure 34. Teva Pharmaceuticals (Israel) Revenue: by Geography 2021
  • Figure 35. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 36. Novartis (Switzerland) Revenue: by Geography 2021
  • Figure 37. Global Dermatology Otc Drug: by Type USD Million (2022-2027)
  • Figure 38. Global Dermatology Otc Drug: by Application USD Million (2022-2027)
  • Figure 39. Global Dermatology Otc Drug: by Form USD Million (2022-2027)
  • Figure 40. Global Dermatology Otc Drug: by Distribution Channels USD Million (2022-2027)
  • Figure 41. South America Dermatology Otc Drug Share (%), by Country
  • Figure 42. Asia Pacific Dermatology Otc Drug Share (%), by Country
  • Figure 43. Europe Dermatology Otc Drug Share (%), by Country
  • Figure 44. MEA Dermatology Otc Drug Share (%), by Country
  • Figure 45. North America Dermatology Otc Drug Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Sun Pharmaceutical (India)
  • Mylan (United States)
  • Dr. Reddy`s (India)
  • Lupin Limited (India)
  • Bayer (Germany)
  • Aurobindo Pharma (India)
  • Johnson & Johnson (United States)
  • GSK plc (United Kingdom)
  • Teva Pharmaceuticals (Israel)
  • Novartis (Switzerland)
Additional players considered in the study are as follows:
Galderma (Switzerland) , China Resources Sanjiu (China) , Livzon Pharm (China) , Almirall (Spain) , Cipla (India) , Other
Select User Access Type

Key Highlights of Report


Sep 2022 248 Pages 86 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Dermatology Otc Drug Market Quantitative research analysis
Global Dermatology Otc Drug Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Dermatology Otc Drug Market is heading robustly to achieve a new growth cycle.
The Concentration Rate of Global Dermatology Otc Drug market is dominated by India Players and may generate healthy valuation by 2027.
  • Increasing Incidence of Dermatology Otc Drug
  • Rising Geriatric Population and Associated Sleep Otc Drug
dominated the Dermatology Otc Drug market. This is attributable to growing trend of "Introduction of Home Sleep Test Kits and Wearable Monitors "

Know More About Global Dermatology Otc Drug Market Report?

Have a Query? Click Here

Other Related Reports

Chlorhexidine Gluconate Wipes Comprehensive Study by Type (CHG/Non-Alcohol Based Wipes, CHG/Alcohol Based Wipes), Application (Surgical Site Infection, Centre Line Associated Bloodstream Infection, C...
$ 3800
Vaccine Transport Boxes Comprehensive Study by Application (Vaccine distribution, Vaccine storage, Clinical trials, Others), End Users (Pharmaceutical companies, Vaccine manufacturers, Government age...
$ 3800
Medical Clothing- Comprehensive Study by Type (Surgical Drapes and Gowns, Facial Protection, Gloves, Others), Application (Health Worker, Patients, Others), End Users (Hospital and Clinics, Ambulator...
$ 3800